Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii

Parasites and Vectors

Volumn 7, Issue 1, 2014, Pages

  Wang, Yanhua ^a   Yin, Hong ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Diagnosis; Gene structure; Invasion; Surface antigen 1; T. gondii; Vaccine

Indexed keywords

BACTERIAL VACCINE; EPITOPE; LIVE VACCINE; MEMBRANE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; SUBUNIT VACCINE; SURFACE ANTIGEN 1; UNCLASSIFIED DRUG; PARASITE ANTIGEN; SAG1 ANTIGEN, TOXOPLASMA;

DIAGNOSTIC PROCEDURE; GENE DELETION; GENE STRUCTURE; HOST CELL; IMMUNE RESPONSE; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MOLECULAR DIAGNOSIS; MORBIDITY; NONHUMAN; PARASITOSIS; POLYMERASE CHAIN REACTION; REVIEW; TOXOPLASMA GONDII; TOXOPLASMOSIS; VIRULENCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; TOXOPLASMA;

PROTOZOA; TOXOPLASMA GONDII;

ANTIGENS, PROTOZOAN; GENE EXPRESSION REGULATION; HUMANS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84899489949     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-7-180     Document Type: Review

References (93)

1. Prevalence of Toxoplasma gondii infection in Myocastor coypus in a protected Italian wetland. Nardoni S, Angelici M, Mugnaini L, Mancianti F, Parasit Vectors 2011 4 240 10.1186/1756-3305-4-240 22196032
2. Detection of circulating antigen in acute experimental infections with Toxoplasma gondii. Raizman RE, Neva FA, Infect Dis 1975 132 44 48 10.1093/infdis/132.1.44
3. Seroprevalence and epidemiological correlates of Toxoplasma gondii infections among patients referred for hospital-based serological testing in Doha Qatar. Abu-Madi MA, Naema Al-Molawi N, Behnke JM, Parasit Vectors 2008 1 39 10.1186/1756-3305-1-39 18937857
4. Toxoplasma gondii infection and liver disease: a case-control study in a northern Mexican population. Alvarado-Esquivel C, Torres-Berumen JL, Estrada-Martínez S, Liesenfeld O, Mercado-Suarez MF, Parasit Vectors 2011 4 75 10.1186/1756-3305-4-75 21569516
5. Toxoplasma gondii infection in humans in China. Zhou P, Chen Z, Li HL, Zheng H, He S, Lin RQ, Zhu XQ, Parasit Vectors 2011 4 165 10.1186/1756-3305-4- 165 21864327
6. Seroprevalence of Toxoplasma gondii infection among horses in Tunisia. Boughattas S, Bergaoui R, Essid R, Aoun K, Bouratbine A, Parasit Vectors 2011 4 218 10.1186/1756-3305-4-218 22107730
7. Serological survey of Toxoplasma gondii in Tibetan mastiffs (Canislupus familiaris) and yaks (Bos grunniens) in Qinghai China. Wang M, Wang YH, Ye Q, Meng P, Yin H, Zhang DL, Parasit Vectors 2012 5 35 10.1186/1756-3305-5-35 22330277
8. Seroprevalence of Toxoplasma gondii infection in slaughtered chickens, ducks, and geese in Shenyang, northeastern China. Yang N, Mu MY, Li HK, Long M, He JB, Parasit Vectors 2012 5 237 10.1186/1756-3305-5-237 23078787
9. Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice. Mévélec MN, Bout D, Desolme B, Marchand H, Magné R, Bruneel O, Buzoni-Gatel D, Vaccine 2005 23 4489 4499 10.1016/j.vaccine.2005.04.025 15935521
10. Sources and reservoirs of Toxoplasma gondii infection on 47 swine farms in Illinois. Dubey JP, Weigel RM, Siegel AM, Thulliez P, Kitron UD, Mitchell MA, Mannelli A, Mateus-Pinilla NE, Shen SK, Kwok OC, Todd KS, J Parasitol 1995 81 723 729 10.2307/3283961 7472862
11. Epitopic analysis of the Toxoplasma gondii major surface antigen SAG1. Velge-Roussel F, Chardès T, Mévélec P, Brillard M, Hoebeke J, Bout D, Mol Biochem Parasit 1994 66 31 38 10.1016/0166-6851(94)90033-7
12. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Debard N, Buzoni-Gatel D, Bout D, Infect Immun 1996 64 2158 2166 8675321
13. Protection of mice from fatal Toxoplasma gondii infection by immunization with P30 antigen in liposomes. Bulow R, Boot hroyd JC, J Immunol 1991 147 3496 3500 1940349
14. Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Petersen E, Nielsen HV, Christiansen L, Spenter J, Vaccine 1998 16 1283 1289 10.1016/S0264-410X(98)00039-5 9682392
15. The conformation of purified Toxoplasma gondii SAG1 antigen, secreted from engineered Pichia pastoris, is adequate for serorecognition and cell proliferation. Biemans R, Gregoire D, Haumont M, Bosseloir A, Garcia L, Jacquet A, Dubeaux C, Bollen A, J Biotechnol 1998 66 137 146 10.1016/S0168-1656(98) 00143-6 9866865
16. Protection of mice and nude rats against toxoplasmosis by a multiple antigenic peptide construction derived from Toxoplasma gondii P30 antigen. Darcy F, Maes P, Gras-Masse H, Auriault C, Bossus M, Deslee D, Godard I, Cesbron MF, Tartar A, Capron A, J Immunol 1992 149 3636 3641 1431132
17. Antigenicity and immunogenicity of P30-derived peptides in experimental models of toxoplasmosis. Godard I, Estaquier J, Zenner L, Bossus M, Auriault C, Darcy F, Gras-Masse H, Capron A, Mol Immunol 1994 31 1353 1363 10.1016/0161-5890(94)90054-X 7997247
18. Anti-SAG1 peptide antibodies inhibit the penetration of Toxoplasma gondii tachyzoites into enterocyte cell lines. Velge-Roussel F, Dimier-Poisson I, Buzoni-Gatel D, Bout D, Parasitol 2001 123 571 578
19. A purified parasite antigen (P30) mediates CD8+ T cell immunity against fatal Toxoplasma gondii infection in mice. Khan IA, Ely KH, Kasper LH, J Immunol 1991 147 3501 3506 1940350
20. Detection and characterization of membrane antigen of Toxoplasma gondii. Handman E, Goding JW, Remington JS, Immunol 1980 124 2578 2583
21. Purification of a major membrane protein of Toxoplasma gondii by immunoabsorption with a monoclonal antibody. Kasper LH, Crabb JH, Pfefferkorn ER, J Immunol 1983 130 2407 2412 6833761
22. Molecular analysis of the gene encoding the major surface antigen of Toxoplasma gondii. Burg JL, Perelman D, Kasper LH, Ware PL, Boothroyd JC, Immunol 1988 141 3584 3591
23. A selector of transcription initiation in the protozoan the protozoan parasite Toxoplasma gondii. Soldati D, Boothroyd JC, Mol Cell Biol 1995 15 87 93 7799972
24. Toxoplasma gondii strain specific transcript level of SAG1 and their association with virulence. Windeck T, Gross U, Parasitol Res 1996 82 715 719 10.1007/s004360050190 8897506
25. Analysis of antigenic domain of GST fused major surface protein (p30) fragments of Toxoplasma gondii. Nam HW, Im KS, Baek EJ, Choi WY, Cho SY, Korean J Parasitol 1996 34 135 141 10.3347/kjp.1996.34.2.135 8925246
26. Molecular weight analysis of soluble antigens from Toxoplasma gondii. Johnson Alan M, McDonald PJ, Neoh SH, J Parasitol 1983 69 459 464 10.2307/3281354 6415262
27. Antibodies to Toxoplosma gondii major surface protein (SAG1-P30) inhibit infection of host cells and are produced in murine intestine after peroral infection. Mineo JR, McLeod R, Mack D, Smith J, Khan IA, Ely KH, Kasper LH, J Immunol 1993 150 3951 3964 7682587
28. Attachment of Toxoplasma gondii to host cell involves major surface protein, SAG-1(P30). Mineo JR, Kasper LH, Exp Parasitol 1994 79 11 20 10.1006/expr.1994.1054 8050521
29. Toxoplasma gondii:The role of parasite and secreted proteins in host cell invasion. Grimwood J, Smith JE, Int J Parasitol 1996 26 69 l173
30. Update on host cell invasion by Toxoplasma gondii. Li XR, Wang YH, Zhao XZ, Zhang DL, Chin J Parasitol 2007 25 154 158
31. Toxoplasma gondii major surface antigen (SAG1): in vitro analysis of host cell binding. Robinson SA, Smith JE, Millner PA, Parasitol 2004 128 391 396 10.1017/S0031182003004736
32. The major surface proteins of Toxoplasma gondii structures and functions. Tomavo S, Curr Top Mcrobiol 1996 219 45 54
33. Similarities between the primary structures of two distinct major surface proteins of Toxoplasma gondii. Cesbron-Delauw MF, Tomavo S, Beauchamps P, Fourmaux MP, Camus D, Capron A, Dubremetz JF, J Biol Chem 1994 269 16217 16222 8206924
34. Acute virulence in mice is associated with markers on chromosome VIII in Toxoplasma gondii. Howe DK, Summers BC, Sibley LD, Infect Immun 1996 64 5193 5198 8945565
35. Surface antigens of Toxoplasma gondii: variations on the theme. Lekutis C, Ferguson DJ, Grigg ME, Camps M, Boothroyd JC, Int J Parasitol 2001 31 1285 1292 10.1016/S0020-7519(01)00261-2 11566296
36. The Cognition and understanding for study on epitopic biology. Wu YZ, Zhu XH, Cur Immunol 1998 18 1 2
37. Molecular dissection of the human B-cell response against Toxoplasma gondii infection by lambda display of cDNA libraries. Beghetto E, Spadoni A, Buffolano W, Del Pezzo M, Minenkova O, Pavoni E, Pucci A, Cortese R, Felici F, Gargano N, Int J Parasitol 2003 33 163 173 10.1016/S0020-7519(02)00256-4 12633654
38. Toxoplasma gondii: immunogenicity and protection by P30 peptides in a murine model. Siachoque H, Guzman F, Burgos J, Patarroyo ME, Gomez Marin JE, Exp Parasitol 2006 114 62 65 10.1016/j.exppara.2006.02.005 16545806
39. Reactivity of synthetic SAG1 (p30) peptide sequences with RH, S273 and beverley strain-induced anti-Toxoplasma gondii antibodies. Kato M, Claveria FG, Maki Y, Sanda K, Tanaka T, Omata Y, Nagasawa H, Suzuki N, Pathobiol 2007 74 50 56 10.1159/000101051
40. Toxoplasma gondii: P30 peptides recognition pattern in human toxoplasmosis. Cardona N, De-la-Torre A, Siachoque H, Patarroyo MA, Gomez-Marin JE, Exp Parasitol 2009 123 199 202 10.1016/j.exppara.2009.06.017 19567250
41. Screening and identification of novel B cell epitopes of Toxoplasma gondii SAG1. Wang YH, Wang GX, Zhang DL, Yin H, Wang M, Parasit Vectors 2013 6 125 10.1186/1756-3305-6-125 23631709
42. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A, Vaccine 1991 146 286 292
43. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. Kang H, Remington JS, Suzuki Y, J Immunol 2000 164 2629 2634 10679102
44. Vaccination against toxoplasmosis: current status and future prospects. Schaap D, Vermeulen AN, Roberts CW, Alexander J, Toxoplasma gondii: the model apicomplexan perspectives and methods London: Academic Press, Weiss LM, Kim K, 1 2007 731 736
45. Role of P30 in host immunity and pathogenesis of T. gondii infection. Kasper LH, Khan IA, Res Immunol 1993 144 45 48 10.1016/S0923-2494(05)80097-5 8451518
46. The induction of acute ileitis by a single microbial antigen of Toxoplasma gondii. Rachinel N, Buzoni-Gatel D, Dutta C, J Immunol 2004 173 2725 2735 15294991
47. Expression of the major surface antigen of Toxoplasma gondii as in soluable glutathione Stransferase fusion. Makioka A, Jpn J Parasitol 1991 40 344
48. Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB/c mice but not in CBA/J mice. Letscher-Bru V, Pfaff AW, Abou-Bacar A, Filisetti D, Antoni E, Villard O, Klein JP, Candolfi E, Infect Immun 2003 71 6615 6619 10.1128/IAI.71.11.6615-6619.2003 14573684
49. Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles. Chuang SC, Ko JC, Chen CP, Du JT, Yang CD, Parasit Vectors 2013 6 34 10.1186/1756-3305-6-34 23398973
50. Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii. Cong H, Gu QM, Jiang Y, He SY, Zhou HY, Yang TT, Li Y, Zhao QL, Parasite Immunol 2005 27 29 35 10.1111/j.1365-3024.2005.00738.x 15813720
51. Manipulation of the immune response to a plasmidoncoded viral antigen by coinoculation with plasmids expressing cytokines. Yiang Z, Ertl HC, Immunity 1995 2 129 1351 10.1016/S1074-7613(95)80001-8 7895169
52. Identification and characterization of Toxoplasma gondii aspartic protease 1 as a novel vaccine candidate against toxoplasmosis. Zhao G, Zhou A, Lu G, Meng M, Sun M, Bai Y, Han Y, Wang L, Zhou H, Cong H, Zhao Q, Zhu XQ, He S, Parasit Vectors 2013 6 175 10.1186/1756-3305-6-175 23768047
53. Establishment of gene vaccinated skin grafting against Toxoplasma gondii infection in mice. Saito S, Aosai F, Rikihisa N, Mun HS, Norose K, Chen M, Kuroki T, Asano T, Ochiai T, Hata H, Ichinose M, Yano A, Vaccine 2001 19 2172 2180 10.1016/S0264-410X(00)00366-2 11228390
54. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Nielsen HV, Lauemøller SL, Christiansen L, Buus S, Fomsgaard A, Petersen E, Infect Immun 1999 67 6358 10569750
55. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Seder RA, Paul WE, Annu Rev Immunol 1994 12 635 637 10.1146/annurev.iy.12.040194.003223 7912089
56. DNA vaccines: designing strategies against parasitic infections. Ivory C, Chadee K, Genet Vaccines Ther 2004 2 17 25 10.1186/1479-0556-2-17 15579202
57. Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice. Cong H, Yuan Q, Zhao Q, Zhao LX, Yin HQ, Zhou HY, He SY, Wang ZY, Parasit Vectors 2014 7 145 10.1186/1756-3305-7-145 24685150
58. Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice. Fachado A, Rodriguez A, Angel SO, Pinto DC, Vila I, Acosta A, Amendoeira RR, Lannes-Vieira J, Vaccine 2003 21 1327 1335 10.1016/S0264-410X(02)00692-8 12615427
59. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protectmice against Toxoplasma gondii. Cong H, Gu QM, Yin HE, Wang JW, Zhao QL, Zhou HY, Li Y, Zhang JQ, Vaccine 2008 26 3913 3921 10.1016/j.vaccine.2008.04.046 18555564
60. Evaluation of the immune response elicited by multi-antigenic DNA vaccine expressing SAG1, ROP2 and GRA2 against Toxoplasma gondii. Xue M, He S, Cui Y, Yao Y, Wang H, Parasitol Int 2008 57 424 429 10.1016/j.parint.2008.05.001 18562245
61. Increased survival time in mice vaccinated with a branched lysine multiple antigenic peptide containing B- and T-cell epitopes from T. gondii antigens. Wang Y, Wang M, Wang G, Pang A, Fu B, Yin H, Zhang D, Vaccine 2011 29 8619 8623 10.1016/j.vaccine.2011.09.016 21939715
62. Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1 (SAG1) and 14-3-3 protein in BALB/c mice. Meng M, He S, Zhao G, Bai Y, Zhou H, Cong H, Lu G, Zhao Q, Zhu XQ, Parasit Vectors 2012 5 273 10.1186/1756-3305-5-273 23181694
63. Compound DNA vaccine encoding SAG1/SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii. Cong H, Zhang M, Xin Q, Wang Z, Li Y, Zhao Q, Zhou H, He S, Parasit Vectors 2013 6 63 10.1186/1756-3305-6-63 23497561
64. Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a guinea pig model. Haumont M, Delhaye L, Garcia L, Jurado M, Mazzu P, Daminet V, Verlant V, Bollen A, Biemans R, Jacquet A, Infect Immun 2000 68 4948 4953 10.1128/IAI.68.9.4948-4953.2000 10948109
65. Immune response against excreted/secreted antigens of Toxoplasma gondii tachyzoites in the murine model. Daryani A, Hosseine AZ, Dalimi A, Vet Parasitol 2003 113 123 134 10.1016/S0304-4017(03)00044-X 12695037
66. 200Gy sterilized Toxoplasma gondii tachyzoites maintain metabolic functions and mammalian cell invasion, eliciting cellular immunity and cytokine response similar to natural infection in mice. Hiramoto RM, Galisteo AJ, Do Nascimento N, De Andrade HF, Vaccine 2002 20 2072 2081 10.1016/S0264-410X(02) 00054-3 11972976
67. Evaluation of a commercial ELISA kit for detection of antibodies against Toxoplasma gondii in serum, plasma and meat juice from experimentally and naturally infected sheep. Glor SB, Edelhofer R, Grimm F, Deplazes P, Basso W, Parasit Vectors 2013 6 85 10.1186/1756-3305-6-85 23561035
68. First report of Toxoplasma gondii seroprevalence in peafowls in Yunnan Province, Southwestern China. Tian YM, Dai FY, Huang SY, Deng ZH, Duan G, Zhou DH, Yang JF, Weng YB, Zhu XQ, Zou FC, Parasit Vectors 2012 5 205 10.1186/1756-3305-5-205 22992281
69. Seroprevalence and risk factors for Toxoplasmosis in HIV infected and non-infected individuals in Bahir Dar, Northwest Ethiopia. Walle F, Kebede N, Tsegaye A, Kassa T, Parasit Vectors 2013 6 15 10.1186/1756-3305-6-15 23324409
70. Detection of Toxoplasma gondii in venous blood from AIDS patients by polymerase chain reaction. Dupouy-Camet J, de Souza SL, Maslo C, Paugam A, Saimot AG, Benarous R, Tourte-Schaefer C, Derouin F, J Clin Microbiol 1993 31 1866 1869 8349765
71. Value of PCR for evaluating occurrence of parasitemia in immunocompromised patients with cerebral and extracerebral toxoplasmosis. Khalifa KES, Roth A, Roth B, Arasteh KN, Janitschke K, J Clin Microbiol 1994 32 2813 2819 7852576
72. A comparative study of Toxoplasma gondii seroprevalence in three healthy Chinese populations detected using native and recombinant antigens. Sun X, Lu H, Jia B, Chang Z, Peng S, Yin J, Chen Q, Jiang N, Parasit Vectors 2013 6 241 10.1186/1756-3305-6-241 23958280
73. Identification of an apically-located antigen that is conserved in sporozoan parasites. Taylor DW, Evans CB, Aley SB, Barta JR, Danforth HD, Proc Natl Acad Sci U S A 1990 37 540 545
74. An identical epitope in Pneumocystis carinii and Toxoplasma gondii causing serological cross reactions. Hassl A, Muller WA, Aspock H, Parasitol Res 1991 77 351 352 10.1007/BF00930914 1714080
75. Detection of immunoglobulin G (IgG) and IgM antibodies to Toxoplasma gondii: evaluation of four commercial immunoassay systems. Hofgärtner WT, Swanzy SR, Bacina RM, Condon J, Gupta M, Matlock PE, Bergeron DL, Plorde JJ, Fritsche TR, J Clin Microbiol 1997 35 3313 3315 9399544
76. Chimeric antigens of Toxoplasma gondii: toward Standardization of toxoplasmosis serodiagnosis using recombinant products. Beghetto E, Spadoni A, Bruno L, Buffolano W, Gargano N, J Clin Microbiol 2006 44 2133 2140 10.1128/JCM.00237-06 16757610
77. Recombinant Toxoplasma gondii surface antigen 1 (P30) expressed in Escherichia coli is recognized by human Toxoplasma-specific immunoglobulin M (IgM) and IgG antibodies. Harning D, Spenter J, Metsis A, Vuust J, Petersen E, Clin Diagn Lab Immunol 1996 3 355 357 8705683
78. High-level expression and purification of immunogenic recombinant SAG1 (P30) of Toxoplasma gondii in Escherichia coli. Chen XG, Gong Y, Hua-Li, Lun ZR, Fung MC, Protein Expr Purif 2001 23 33 37 10.1006/prep.2001.1483 11570843
79. Diagnosis of human toxoplasmosis by using the recombinant truncated surface antigen 1 of Toxoplasma gondii. Wu K, Chen XG, Li H, Yan H, Yang PL, Lun ZR, Zhu XQ, Diagn Microbiol Infect Dis 2009 64 261 266 10.1016/j.diagmicrobio. 2009.02.009 19359122
80. Evaluation of a recombinant multiepitope peptide for serodiagnosis of Toxoplasma gondii infection. Dai JF, Jiang M, Wang YY, Qu LL, Gong RJ, Si J, Clin Vaccine Immunol 2012 19 338 342 10.1128/CVI.05553-11 22219311
81. Rapid prenatal diagnosis of congenital Toxoplasma infection by using polymerase chain reaction and amniotic fluid. Grover CM, Thulliez P, Remington JS, Boothroyd JC, J Clin Microbiol 1990 28 2297 2301 2229355
82. Detection of Toxoplasma gondii by competitive DNA amplification of bronchoalveolar lavage samples. Bretagne S, Costa JM, Vidaud M, Tran J, Nhieu V, Fleury-Feith J, J Infect Dis 1993 168 1585 1588 10.1093/infdis/168.6.1585 8245552
83. Identification of a 200- to 300-fold repetitive 529 bp DNA fragment in Toxoplasma gondii, and its use for diagnostic and quantitative PCR. Homan WL, Vercammen M, De Braekeleer J, Verschueren H, Int J Parasitol 2000 30 69 75 10.1016/S0020-7519(99)00170-8 10675747
84. Comparison of two DNA targets for the diagnosis of toxoplasmosis by real-time PCR using fluorescence resonance energy transfer hybridization probes. Reischl U, Bretagne S, Kruger D, Ernault P, Costa JM, BMC Infect Dis 2003 3 7 10.1186/1471-2334-3-7 12729464
85. Variation of B1 gene and AF146527 repeat element copy numbers according to Toxoplasma gondii strains assessed using real-time quantitative PCR. Costaa JM, Bretagnea S, J Clin Microbiol 2012 50 1452 1454 10.1128/JCM.06514-11 22259209
86. The role of stage specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS. Contini C, Cultrera R, Seraceni S, Segala D, Romani R, Fainardi E, Cinque P, Lazzarin A, Delia S, J Med Microbiol 2002 51 879 890 12435069
87. Polymerase chain reaction for detection of Toxoplasma gondii. Savva D, Morris JC, Johnson JD, Holliman RE, J Med Microbiol 1990 31 25 31
88. Diagnosis of Toxoplasma gondii in cardiac transplant recipients using the polymerase chain reaction. Holliman R, Johnson J, Savva D, Cary N, Wreghitt T, Clin Pathol 1992 45 931 932 10.1136/jcp.45.10.931
89. Loop-mediated isothermal amplification of DNA. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T, Nucleic Acids Res 2000 28 63 10.1093/nar/28.12.e63 10871386
90. Stability of loop-mediated isothermal amplification (LAMP) reagents and its amplification efficiency on crude trypanosome DNA templates. Thekisoe OMM, Bazie RSB, Coronel-Servian AM, Sugimoto C, Kawazu S, Inoue N, J Vet Med Sci 2009 71 471 475 10.1292/jvms.71.471 19420851
91. Development of loop-mediated isothermal amplification (LAMP) as a diagnostic tool of toxoplasmosis. Krasteva D, Toubiana M, Hartati S, Kusumawati A, Dubremetz JF, Widada JS, Vet Parasitol 2009 162 327 331 10.1016/j.vetpar. 2009.03.014 19356855
92. Specific, sensitive, and rapid diagnosis of active toxoplasmosis by a loop-mediated isothermal amplification method using blood samples from patients. Lau YL, Meganathan P, Sonaimuthu P, Thiruvengadam G, Nissapatorn V, Chen Y, J Clin Microbiol 2010 48 3698 3702 10.1128/JCM.00462-10 20660217
93. Loop-mediated isothermal amplification (LAMP): Early detection of Toxoplasma gondii infection in mice. Kong QM, Lu SH, Tong QB, Lou D, Chen R, Zheng B, Kumagai T, Wen LY, Ohta N, Zhou XN, Parasit Vectors 2012 5 2 10.1186/1756-3305-5-2 22214421